Deals
A mostly black box since emerging with more than a billion dollars in hand, Xaira Therapeutics is slowly pulling back the curtain, revealing plans to find partners and validate its pipeline.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Nuvisan Pharma Services announces its acquisition of Inamed GmbH, an international CRO specialized in clinical trials with patients living with respiratory and rare diseases.
iOnctura B.V., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces the closing of a EUR 15 million Series A financing.
Recipharm announces that it has this morning acquired 4,881,437 Consort Shares, representing 9.9 per cent. of the existing issued share capital of Consort Medical, at 1,010 pence per share and a further 118,563 Consort Shares, representing 0.2 per cent. of the existing issued share capital of Consort Medical at 1,000 pence per share.
Heidelberg Pharma AG announced that it has secured a financing commitment from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany
Voluntary public share buyback offer against cash payment in a purchase price range of EUR 1.60 to EUR 1.85 per share
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models
Sensyne Health plc, the British Clinical AI technology company, announces its Interim Results for the 6 months ended 31 October 2019.
Evotec SE announced an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company’s financial performance.
The funds will allow the company to accelerate the development of its chemotherapy drug candidate targeting solid tumors
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities